Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib in early Alzheimer's disease in APOE4 carriers
2021-002687-41Phase 2Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Aug 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obicetrapib in Alzheimer's disease (AD), sponsored by NewAmsterdam Pharma. Primary endpoint: Change from baseline in CSF and plasma apolipoprotein and HDL-related pharmacodynamic markers at Day 168. Started Aug 2021; status: completed.
02
Drugs
obicetrapib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2021-002687-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002687-41.